Research programme: matrix metalloprotease inhibitors - Queens University of Belfast

Drug Profile

Research programme: matrix metalloprotease inhibitors - Queens University of Belfast

Alternative Names: Matrix metalloprotease inhibitors research programme - Queen's University of Belfast

Latest Information Update: 02 Apr 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Queens University Belfast
  • Class
  • Mechanism of Action Collagenase inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 02 Apr 2003 No development reported - Preclinical for Cancer in Northern Ireland (unspecified route)
  • 03 Jul 2001 New profile
  • 03 Jul 2001 Preclinical development for Cancer in Northern Ireland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top